- Home
- FF vs MOLN Comparison
FF vs MOLN Comparison
Compare FF & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FF
- MOLN
- Stock Information
- Founded
- FF N/A
- MOLN 2004
- Country
- FF United States
- MOLN Switzerland
- Employees
- FF N/A
- MOLN N/A
- Industry
- FF Major Chemicals
- MOLN
- Sector
- FF Industrials
- MOLN
- Exchange
- FF Nasdaq
- MOLN Nasdaq
- Market Cap
- FF 224.1M
- MOLN 218.1M
- IPO Year
- FF N/A
- MOLN 2021
- Fundamental
- Price
- FF $5.18
- MOLN $5.29
- Analyst Decision
- FF Strong Buy
- MOLN Hold
- Analyst Count
- FF 1
- MOLN 1
- Target Price
- FF $0.80
- MOLN $4.50
- AVG Volume (30 Days)
- FF 365.6K
- MOLN 15.4K
- Earning Date
- FF 11-08-2024
- MOLN 08-26-2024
- Dividend Yield
- FF 4.63%
- MOLN N/A
- EPS Growth
- FF 24.25
- MOLN N/A
- EPS
- FF 0.82
- MOLN N/A
- Revenue
- FF $273,839,000.00
- MOLN $7,105,397.00
- Revenue This Year
- FF N/A
- MOLN N/A
- Revenue Next Year
- FF N/A
- MOLN $29.41
- P/E Ratio
- FF $6.32
- MOLN N/A
- Revenue Growth
- FF N/A
- MOLN N/A
- 52 Week Low
- FF $4.15
- MOLN $3.32
- 52 Week High
- FF $8.36
- MOLN $12.70
- Technical
- Relative Strength Index (RSI)
- FF 35.96
- MOLN 45.78
- Support Level
- FF $5.07
- MOLN $5.16
- Resistance Level
- FF $5.28
- MOLN $5.48
- Average True Range (ATR)
- FF 0.23
- MOLN 0.36
- MACD
- FF -0.05
- MOLN -0.09
- Stochastic Oscillator
- FF 37.43
- MOLN 15.50
About FF FutureFuel Corp. Common shares
FutureFuel Corp makes and sells diversified chemical products, bio-based fuel products, and specialty chemical products. The company is organized into two segments based on product type: biofuels and chemicals. The biofuel segment sells biodiesel and other petroleum products. Its fuels are made from a mix of diesel, vegetable oils, and grease feedstock. The chemicals segment sells products that are used in the production of agricultural chemicals, which include herbicides, coatings, and cleaning products, such as detergents.
About MOLN Molecular Partners AG
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.